SUBSCRIBE
SUBSCRIBE

Abcuro, Inc.

NEWS
Job Trends
BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces
BioSpace has named 50 life sciences companies to its 2026 Best Places to Work list. AbbVie, Amneal Pharmaceuticals and BridgeBio executives share what makes their organizations special.
November 4, 2025
 · 
7 min read
 · 
Angela Gabriel
A human hand showing dollar golden coins in the jar with a colored background. Collage Art of finance
Funding
Abcuro Secures $200 Million Series C to Push Rare Muscle Disease Treatment
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion body myositis through clinical trials. Now, Abcuro is eyeing a regulatory submission and potential launch.
February 12, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
IN THE PRESS
Press Releases
Abcuro to Present Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting
November 3, 2025
 · 
2 min read
Press Releases
Abcuro Appoints George Eldridge as Chief Financial Officer
August 18, 2025
 · 
3 min read
Press Releases
Abcuro Appoints Courtney Cupples as Chief Commercial Officer
June 9, 2025
 · 
3 min read
Press Releases
Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual Meeting
March 11, 2025
 · 
2 min read
Press Releases
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis
February 12, 2025
 · 
3 min read
Press Releases
Abcuro Announces Participation in Upcoming Investor Conferences
November 11, 2024
 · 
1 min read
Drug Development
Abcuro Completes Enrollment of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart for the Treatment of Inclusion Body Myositis
June 25, 2024
 · 
3 min read
Business
Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors
December 6, 2023
 · 
2 min read
Drug Development
Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis
November 13, 2023
 · 
3 min read
Genetown
Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline
August 17, 2023
 · 
4 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS